CD8A and neoplasm: According to a recent study, MHC class I molecules make an important impact on presenting tumor-specific or tumor-associated peptides to activate CD8+ T cell immune response and can be used as the indicator of clinical application of immune-checkpoint inhibitors such as anti-PD-L1 immunotherapy (29, 30).